ACRS - Company ID 0001557746
The table below shows Aclaris Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $7.83M | $18.72M | $31.25M | $29.75M | $6.76M | $6.48M |
| Cost of revenue | $2.09M | $2.79M | $3.42M | $4.02M | $4.71M | $5.13M |
| Gross profit | - | - | - | - | - | - |
| R&D | $52.65M | $33.59M | $98.38M | $77.81M | $43.81M | $29.34M |
| SG&A |
Aclaris Therapeutics, Inc. reported annual revenue of $7.83M for fiscal year 2025. That is down 58.2% from $18.72M in fiscal 2024. Over the 9 fiscal years shown, annual revenue grew from $1.68M (FY 2017) to $7.83M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $21.97M |
| $22.20M |
| $32.41M |
| $25.13M |
| $23.62M |
| $20.53M |
| Operating income | -$76.38M | -$141.93M | -$97.36M | -$89.85M | -$89.72M | -$50.91M |
| Income tax | - | - | -$367.00K | - | - | -$182.00K |
| Net income | -$64.92M | -$132.06M | -$88.48M | -$86.91M | -$90.86M | -$51.02M |
| EPS (diluted) | -$0.53 | -$1.71 | -$1.27 | -$1.33 | -$1.60 | -$1.20 |